

ATTORNEY'S DOCKET NO. S1383/7002 (ERG)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Richard S. Blumberg et al.

Serial No:

08/899,856

Filed:

July 24, 1997

For:

RECEPTOR SPECIFIC TRANSPITHELIAL TRANSPORT

THERAPEUTICS

Examiner:

T. Cunningham

Art Unit:

1644

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this document is being placed in the United States mail with first-class postage attached, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the 2nd day of April, 1999.

Edward R. Gates

Sir:

RESPONSE

In response to the Restriction Requirement dated February 1, 1999, applicants elect:

- (A) the FcRn binding partners "IgG Fc fragments"
- (B) the bioactive substances: "proteins or peptides"; and
- (C) the method of delivery "oral delivery".

Respectfully Submitted,

Edward R. Gates

Reg. No. 31,616

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, MA 02210-2211

(617)720-3500

Docket No. S1383/7002 (ERG) April 2, 1999 xApril 3, 1999